MacroGenics Inc
MGNX
查看详细走势图
2.760USD
-0.170-5.80%
收盘 03/30, 16:00（美东）报价延迟15分钟
66.30M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.80%
5天
-5.48%
1月
+42.27%
6月
+64.29%
今年开始到现在
+71.43%
1年
+119.05%
查看详细走势图
TradingKey MacroGenics Inc股票评分
单位: USD 更新时间: 2026-03-30操作建议
MacroGenics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名70/391位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价4.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
MacroGenics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
MacroGenics Inc亮点
亮点风险
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
业绩高增长
公司营业收入稳步增长，连续3年增长154.47%
利润高增长
公司净利润处于行业前列，最新年度总收入149.50M美元
估值合理
公司最新PE估值-2.34，处于3年历史合理位
机构减仓
最新机构持股37.93M股，环比减少44.94%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值4.23M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.44
分析师目标
根据
7
位分析师
持有
评级
4.000
目标均价
+36.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
MacroGenics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
MacroGenics Inc简介
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
公司代码MGNX
公司MacroGenics Inc
CEORisser (Eric)
网址https://www.macrogenics.com/
相关品种
